search
Back to results

Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin

Primary Purpose

Autism Spectrum Disorder

Status
Completed
Phase
Phase 3
Locations
Belgium
Study Type
Interventional
Intervention
Oxytocin
Placebo
Sponsored by
KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Autism Spectrum Disorder focused on measuring Oxytocin, Eye Contact, Mirror System, Transcranial Magnetic Stimulation

Eligibility Criteria

18 Years - 35 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male
  • Young adults (between 18 - 35 y/o)
  • Right-handed
  • Official diagnosis of Autism Spectrum Disorders (for ASD participants)

Exclusion Criteria:

  • Female
  • Left-handed
  • Any neuro(psycho)logical / psychiatric illness (for healthy controls)
  • Motor dysfunctions of the hands / arms
  • Any contradiction to TMS research as assessed with the TMS screening list: no metal objects in the body (e.g. pacemaker, coronary bypass clips, implants, medication pumps, ...), history of brain trauma in the past (e.g. meningitis, epilepsy, surgery, ...) or history of drug and/or alcohol abuse.

Sites / Locations

  • Katholieke Universiteit Leuven

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Oxytocin (OXT) spray

Placebo (PL) spray

Arm Description

Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).

Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).

Outcomes

Primary Outcome Measures

Change from baseline in socially adaptive mirroring as measured by TMS
After a single dose of nasal spray, TMS will be applied to assess mirror-motor mapping during the observation of socially relevant vs. irrelevant visuomotor information.

Secondary Outcome Measures

Change from baseline in mirroring of others' actions as measured by TMS
After a single dose of nasal spray, TMS will be applied to assess basic mirror-motor mapping of observed actions.
Change from baseline in corticospinal excitability as measured by TMS
After a single dose of nasal spray, TMS will be applied to assess corticospinal excitability when the participant is at rest (without any visuomotor information).
Change from baseline in total fixation duration towards the eye region of the model.
During movement observation, participants' viewing behavior will be monitored by means of head-mounted eye tracking technology.

Full Information

First Posted
August 16, 2018
Last Updated
February 3, 2020
Sponsor
KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT03640156
Brief Title
Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
Official Title
To Mirror or Not to Mirror Upon Perceived Eye Contact? The Effect of Oxytocin on Socially Adaptive Mirror System Functioning in Autism
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
July 26, 2018 (Actual)
Primary Completion Date
December 19, 2019 (Actual)
Study Completion Date
December 19, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
KU Leuven

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study investigates the efficacy of a single-dose of exogenous oxytocin administration on socially adaptive mirror-motor mapping in participants with Autism Spectrum Disorders. A placebo-controlled cross-over trial will be conducted: each participant will receive both a single-dose of placebo and oxytocin in two sessions separated by one week. The order of nasal spray will be randomised across participants. Mirror-motor mapping will be assessed by transcranial magnetic stimulation (TMS), a standard technique to investigate mirror system activity.
Detailed Description
The brain's action observation network or 'mirror system' supports a variety of socio-cognitive functions, as it enables us to internally simulate and understand others' actions, emotions and intentions. Generally, mirror responses are larger upon the observation of actions accompanied by relevant information for the observer, such as direct eye contact from the actor. In other words, 'mirroring' is adaptively modulated according to the social salience of the observed actions (i.e. it is socially adaptive). Individuals with Autism Spectrum Disorders (ASD) are known to endure difficulties with correctly recognizing eye contact as a communicative cue. Instead, they tend to experience eye contact as stressful and arousing. It is therefore hypothesized that, upon the observation of actions combined with salient gaze cues from the actor, these mirroring processes will not be adaptively modulated in participants with ASD. As appropriate processing of eye contact is a key aspect of (non-verbal) communicative behavior, the investigator will investigate the efficacy of a single dose of intranasal oxytocin administration for enhancing socially-adaptive mirroring in ASD. Oxytocin is a neuropeptide that acts as a regulator social brain areas. On a behavioral level, it is known to enhance the saliency of observed social cues and to improve prosocial behavior. As such, it is regarded a promising intervention for alleviating the social and communicative deficits in ASD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorder
Keywords
Oxytocin, Eye Contact, Mirror System, Transcranial Magnetic Stimulation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oxytocin (OXT) spray
Arm Type
Experimental
Arm Description
Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
Arm Title
Placebo (PL) spray
Arm Type
Placebo Comparator
Arm Description
Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Other Intervention Name(s)
Syntocinon (product code RVG 03716)
Intervention Description
A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Primary Outcome Measure Information:
Title
Change from baseline in socially adaptive mirroring as measured by TMS
Description
After a single dose of nasal spray, TMS will be applied to assess mirror-motor mapping during the observation of socially relevant vs. irrelevant visuomotor information.
Time Frame
30 minutes after spray administration
Secondary Outcome Measure Information:
Title
Change from baseline in mirroring of others' actions as measured by TMS
Description
After a single dose of nasal spray, TMS will be applied to assess basic mirror-motor mapping of observed actions.
Time Frame
30 minutes after spray administration
Title
Change from baseline in corticospinal excitability as measured by TMS
Description
After a single dose of nasal spray, TMS will be applied to assess corticospinal excitability when the participant is at rest (without any visuomotor information).
Time Frame
30 minutes after spray administration
Title
Change from baseline in total fixation duration towards the eye region of the model.
Description
During movement observation, participants' viewing behavior will be monitored by means of head-mounted eye tracking technology.
Time Frame
30 minutes after spray administration
Other Pre-specified Outcome Measures:
Title
Change from baseline in saliva-based oxytocin concentrations
Description
Saliva samples will be collected before nasal spray administration and after the experimental procedure to be able to monitor the pharmacokinetics of oxytocin.
Time Frame
Before and 60 minutes after spray administration
Title
Change from baseline in Public Self-Awareness Score on Situational Self-Awareness Scale (SSAS)
Description
Informant-based self-report scale to assess public self-awareness in a specific situation as measured by SSAS. Likert scale: I totally agree (1) - I totally disagree (10); lower scores indicate more public self-awareness.
Time Frame
60 minutes after spray administration
Title
Change from baseline in Arousal and Pleasure on the Self-Assessment Manikin (SAM)
Description
Informant-based scale to assess self-reported arousal and pleasure in a specific situation as measured by SAM. Likert scale: Pleasant / Not aroused (1) - Unpleasant / Aroused (9). Higher scores indicate more arousal and less pleasure.
Time Frame
60 minutes after spray administration

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male Young adults (between 18 - 35 y/o) Right-handed Official diagnosis of Autism Spectrum Disorders (for ASD participants) Exclusion Criteria: Female Left-handed Any neuro(psycho)logical / psychiatric illness (for healthy controls) Motor dysfunctions of the hands / arms Any contradiction to TMS research as assessed with the TMS screening list: no metal objects in the body (e.g. pacemaker, coronary bypass clips, implants, medication pumps, ...), history of brain trauma in the past (e.g. meningitis, epilepsy, surgery, ...) or history of drug and/or alcohol abuse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaat Alaerts
Organizational Affiliation
KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
Katholieke Universiteit Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27939365
Citation
Prinsen J, Bernaerts S, Wang Y, de Beukelaar TT, Cuypers K, Swinnen SP, Alaerts K. Direct eye contact enhances mirroring of others' movements: A transcranial magnetic stimulation study. Neuropsychologia. 2017 Jan 27;95:111-118. doi: 10.1016/j.neuropsychologia.2016.12.011. Epub 2016 Dec 8.
Results Reference
background
PubMed Identifier
29494953
Citation
Prinsen J, Brams S, Alaerts K. To mirror or not to mirror upon mutual gaze, oxytocin can pave the way: A cross-over randomized placebo-controlled trial. Psychoneuroendocrinology. 2018 Apr;90:148-156. doi: 10.1016/j.psyneuen.2018.02.016. Epub 2018 Feb 22.
Results Reference
background
Links:
URL
https://gbiomed.kuleuven.be/english/research/50000743/nrrg1/neuromodulation-laboratory
Description
Related Information

Learn more about this trial

Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin

We'll reach out to this number within 24 hrs